Importance of TIMI 3 flow

Circulation

Volumn 104, Issue 6, 2001, Pages 624-626

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angioplasty; Catheterization; Editorials; Myocardial infarction; Platelet aggregation inhibitors; Stents; Thrombolysis

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; CLINICAL TRIAL; EDITORIAL; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE REPERFUSION; HUMAN; PRIORITY JOURNAL;

EID: 0035822599     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.104.6.624     Document Type: Editorial

References (25)

1. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded?
2. The Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I findings
3. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: A report from TIMI II
4. Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty
5. The open-artery theory is alive and well: Again
6. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
7. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction
8. Emergency department: Rapid identification and treatment of patients with acute myocardial infarction
9. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction
10. Relationship of symptomonset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
11. Longer thrombolysis door-to-needle times are associated with increased mortality in acute myocardial infarction: An analysis of 85,589 patients in the National Registry of Myocardial Infarction 2+3
12. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: Analysis from the Primary Angioplasty in Myocardial Infarction trials
13. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy of acute myocardial infarction: A quantitative review
14. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators
15. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy
16. Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction
17. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
18. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results
19. Early coronary intervention following pharmacologic therapy for acute myocardial infarction: The combined TIMI 10B-TIMI 14 experience
20. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial
21. Abciximab facilitates the rate and extent of thrombolysis: Results of TIMI 14 trial
22. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy
23. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs
24. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results
25. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial